Plus   Neg

Stock Alert: InflaRx Shares Up 71.99% In After-Market

Shares of InflaRx N.V. (IFRX) surged over 70% in after-hours, extending its 8% gain in the regular trading session. The stock closed Tuesday's regulat trade at $3.82, up 29 cents or 8.22%. Trading volume surged to 2.54 million shares versus an average vlume of 613K shares.

The company, on March 31, announced the enrollment of the first patient into a randomized clinical trial investigating the safety and efficacy of IFX-1, the company's monoclonal anti-C5a antibody, in patients with severe COVID-19-induced pneumonia.

InflaRx said it received initial positive human data from two initial patients suffering from COVID-19-induced severe pneumonia who were treated with BDB-001, an anti-C5a antibody produced by BDB from the IFX-1 cell line, in China.

IFX-1 is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT